Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

This article has a correction. Please see:

Correction: Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC - September 01, 2022

PDF +
Supplementary
Material

Immunotherapy biomarkers

Original research

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC

Online download statistics by month:

Online download statistics by month: February 2022 to August 2024

	Abstract	Full	Pdf
Feb 2022	516	525	125
Mar 2022	427	435	203
Apr 2022	188	196	82
May 2022	230	236	89
Jun 2022	135	139	51
Jul 2022	138	140	43
Aug 2022	161	167	46
Sep 2022	123	124	102
Oct 2022	123	127	31
Nov 2022	113	113	31
Dec 2022	91	91	12
Jan 2023	89	89	33
Feb 2023	100	100	17
Mar 2023	51	53	29
Apr 2023	80	80	26
May 2023	78	79	18
Jun 2023	61	61	20
Jul 2023	49	49	21
Aug 2023	37	38	16
Sep 2023	43	44	22
Oct 2023	38	40	16
Nov 2023	41	41	11
Dec 2023	70	70	27
Jan 2024	85	88	22
Feb 2024	30	30	12
Mar 2024	48	48	69
Apr 2024	33	34	21
May 2024	33	34	18
Jun 2024	36	35	18
Jul 2024	56	58	17
Aug 2024	28	26	10
Total	3331	3390	1258